Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 6.11B |
| Revenue (ttm) | 331.26M |
| Net Income (ttm) | 163.08M |
| Shares Out | 137.95M |
| EPS (ttm) | 1.13 |
| PE Ratio | 37.45 |
| Forward PE | 30.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $42.17 |
| Previous Close | $42.89 |
| Change ($) | -0.72 |
| Change (%) | -1.68% |
| Day's Open | 42.92 |
| Day's Range | 41.97 - 43.08 |
| Day's Volume | 418,613 |
| 52-Week Range | 25.17 - 56.40 |
SAN DIEGO, July 12, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZ...
Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV
SAN DIEGO, June 22, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & Johnso...
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc (NASDAQ: HALO) to gain access to Halozyme's Enhanze dr...
LONDON & SAN DIEGO--(BUSINESS WIRE)--ViiV HC and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to develop ultra-long-acting HIV medicines
LONDON and SAN DIEGO, June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholder...
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, June 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced abstracts and presentations by its collaborators for the 2021 American Society of Clinical Oncology (AS...
SAN DIEGO, May 28, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: The Goldman Sachs 42nd Annual Global He...
SAN DIEGO, May 21, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Pharmaceutica N.V. (Janssen) received two positive opinions from the Committee for Medici...
Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 19.35% and 5.19%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 10, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2021 and provided an update on its recent corpor...
SAN DIEGO, April 29, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the BofA Secu...
SAN DIEGO, April 20, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1:30...
In some ways, this healthcare stock is outside his wheelhouse. But there could be attractions.
It's worth putting a few of your eggs into this basket if you're worried about a big increase in prices.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Sometimes valuation metrics can be deceiving.
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the prici...
Investors liked what they saw in the company's fourth-quarter earnings release.
Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates.
Shares of Halozyme Therapeutics (NASDAQ:HALO) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 308.33% over the past year to $0.50, w...
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it i...
Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA) approval of ...
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo®, a fixed-dose combination of Perjeta® (pertu...
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popula...
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on the market a...
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and licen...
DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizo...
SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside chat pres...
SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has r...
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food and Drug ...
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) da...
The shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) are up 3.6% to trade at $32.77 at last check, after earlier hitting an all-time high of $33.23.
Halozyme Therapeutics boosted its EPS and sales guidance for the year, buoyed by partnerships with big drugmakers such as Roche and Johnson & Johnson, sparking HALO stock to a record high. The post Halo...
Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call Transcript
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that w...
SAN DIEGO, Sept. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.
About HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilita... [Read more...]
| Industry Biotechnology | Founded 1998 |
| CEO Helen Torley | Employees 136 |
| Stock Exchange NASDAQ | Ticker Symbol HALO |
Analyst Forecasts
According to 12 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is 52.40, which is an increase of 24.26% from the latest price.